Welcome to LookChem.com Sign In|Join Free

CAS

  • or

75665-88-2

Post Buying Request

75665-88-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

75665-88-2 Usage

General Description

Ethanone, 1-[5-methoxy-2-nitro-4-(phenylmethoxy)phenyl]-, also known as 5-MeO-DiPT, is a synthetic chemical compound that belongs to the tryptamine class. It is a psychedelic hallucinogen and is structurally related to dimethyltryptamine. 5-MeO-DiPT is known to produce profound sensory distortions, intense visual and auditory hallucinations, and altered states of consciousness. It is psychoactive and may have the potential for misuse and abuse. The chemical has been listed as a controlled substance in some countries and its sale and possession are regulated. Its effects on the human body and long-term health consequences are not fully understood.

Check Digit Verification of cas no

The CAS Registry Mumber 75665-88-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,6,6 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 75665-88:
(7*7)+(6*5)+(5*6)+(4*6)+(3*5)+(2*8)+(1*8)=172
172 % 10 = 2
So 75665-88-2 is a valid CAS Registry Number.

75665-88-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(5-methoxy-2-nitro-4-phenylmethoxyphenyl)ethanone

1.2 Other means of identification

Product number -
Other names 6-Nitro-O-benzylacetovanillone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:75665-88-2 SDS

75665-88-2Relevant articles and documents

Heterocyclic compound, preparation method and application thereof

-

, (2020/07/02)

The invention relates to a heterocyclic compound in the technical field of medicines. The compound is represented by a structural general formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, X, Y, Z, Cy1, Cy2, m, n and t have the meanings given in the specification; in addition, the invention also discloses an application of the compound and the pharmaceuticallyacceptable salt thereof in preparation of drugs for treating diseases caused by abnormal high expression of tyrosine kinase, especially application in preparation of drugs for treating and preventingcancers.

CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS

-

, (2019/07/13)

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

Quinoline or quinazoline derivatives as well as preparation method and application thereof

-

, (2017/04/11)

The invention relates to quinoline or quinazoline derivatives as well as a preparation method and an application thereof, namely, the quinoline or quinazoline derivatives shown as the formula I as well as pharmaceutically acceptable salts and hydrates or prodrugs of the quinoline or quinazoline derivatives. The structure is shown in the specification, wherein A1, A2, R1, R2, R3, R4, R5, R6, X, Y, Z, M, W, Cy1, Cy2, m and n are defined in the specification. The invention further relates to the function of the compounds in the general formula I for inhibiting MET kinase and the application of the compounds as well as the pharmaceutically acceptable salts and hydrates of the compounds in preparation of drugs for treating diseases caused by abnormal high expression of the MET kinase, in particular to the application in preparation of drugs for treating and preventing cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 75665-88-2